NASDAQ:CLLS Cellectis Q1 2025 Earnings Report $1.90 -0.09 (-4.47%) As of 01:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Cellectis EPS ResultsActual EPS-$0.18Consensus EPS -$0.15Beat/MissMissed by -$0.03One Year Ago EPSN/ACellectis Revenue ResultsActual Revenue$12.03 millionExpected Revenue$12.71 millionBeat/MissMissed by -$683.00 thousandYoY Revenue GrowthN/ACellectis Announcement DetailsQuarterQ1 2025Date5/12/2025TimeAfter Market ClosesConference Call DateMonday, May 12, 2025Conference Call Time4:00PM ETUpcoming EarningsCellectis' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025Conference Call ResourcesPress Release (6-K)Press ReleaseInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Press ReleaseInterim report Cellectis Earnings HeadlinesCellectis files $200M mixed shelf offeringJuly 2, 2025 | msn.comCellectis Reports Results from Shareholders Meeting Held on June 26, 2025 - MorningstarJune 27, 2025 | morningstar.comMThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 17 at 2:00 AM | Crypto Swap Profits (Ad)Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025June 26, 2025 | globenewswire.comCellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal yearMay 29, 2025 | investing.comCellectis S.A. announces board change and meetingMay 22, 2025 | investing.comSee More Cellectis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your email. Email Address About CellectisCellectis (NASDAQ:CLLS) is a clinical-stage biopharmaceutical company specializing in allogeneic chimeric antigen receptor T-cell (CAR-T) therapies engineered with its proprietary TALEN® gene-editing technology. The company focuses on developing off-the-shelf cellular immunotherapies designed to target hematologic malignancies and solid tumors. By using donor-derived T cells, Cellectis aims to streamline manufacturing processes and deliver treatments more rapidly than traditional autologous approaches. Founded in 1999 and headquartered in Paris, France, Cellectis has built a comprehensive research and development platform that integrates gene editing, cell line engineering, and process development. The company entered the Nasdaq market in 2015, marking a pivotal step in its growth strategy. Under the leadership of founder and CEO Dr. André Choulika, Cellectis has expanded its TALEN technology repertoire and established partnerships to enhance clinical translational capabilities. Beyond its Paris headquarters, Cellectis maintains research sites in New York and operates GMP-compliant manufacturing facilities across Europe and the United States. Its global clinical pipeline includes multiple allogeneic CAR-T candidates targeting indications such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and select solid tumors. Collaborative agreements with pharmaceutical companies and academic centers support the company’s efforts to explore novel targets and combination regimens. Looking forward, Cellectis is advancing pivotal clinical trials for its lead candidates while investing in next-generation gene-editing solutions to improve safety profiles and therapeutic efficacy. With a growing footprint in major markets and a commitment to innovation, the company is strategically positioned to address unmet needs in oncology and drive the broader adoption of allogeneic cell therapies.Written by Jeffrey Neal JohnsonView Cellectis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Citigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting Cycle Upcoming Earnings American Express (7/18/2025)HDFC Bank (7/18/2025)3M (7/18/2025)Southern Copper (7/18/2025)Charles Schwab (7/18/2025)Truist Financial (7/18/2025)NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Alphabet (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
